Current Therapeutic Strategies in Clinical Urology

Crane, Alice; Isharwal, Sudhir; Zhu, Hui

doi:10.1021/acs.molpharmaceut.8b00383

Cited by 6 publications

(8 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They have both biocompatibility and functionality and have been widely used in the diagnosis and treatment of a variety of diseases. Among the advanced biomaterial, the hydrogel has been commonly used for drug delivery because of its high-water content and similar natural living tissues ( Crane et al, 2018 ; Qian et al, 2020 ; Yang et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Injectable, Adhesive, and Self-Healing Composite Hydrogels Loaded With Oxybutynin Hydrochloride for the Treatment of Overactive Bladder in Rats

Sun

Wang

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Object: The aim of this study was to prepare injectable, adhesive, and self-healing composite hydrogels loaded with oxybutynin hydrochloride and verify its function in the treatment of overactive bladder.Method: The ultraviolet (UV) absorption of oxybutynin (Oxy) in the solution was detected using a UV spectrophotometer at 233 nm, and the cumulative drug release was calculated using Origin software. L929 mouse fibroblasts were used to test cell adhesion to OCP50 and OCP100 hydrogels. Both FT-IR and NMR overactive bladder demonstrated that Dex was oxidized to PDA with aldehyde groups. Urodynamic examinations were performed 24 h after intraperitoneal injection in the rat model. The relative expression levels of Orai1 and STIM1 were detected by western blot (WB) and QPCR.Results: After loading Oxy, the shear adhesion under the wet conditions of OCP50 and OCP100 was higher than CP50 and CP100 (p < 0.05), and both were suitable for intravaginal administration. After 72 h of release, oxybutynin released 82.8% in OCP100 hydrogel and 70% in OCP50. Compared to the model, OCP50, CP100, and OCP100 relieved the overactive bladder and inhibited the expression of Orail and STIM1.Conclusions: Oxybutynin hydrogel could provide relief to overactive bladder by decreasing the expression of Orail and STIM1 in rats.

show abstract

Section: Introductionmentioning

confidence: 99%

Injectable, Adhesive, and Self-Healing Composite Hydrogels Loaded With Oxybutynin Hydrochloride for the Treatment of Overactive Bladder in Rats

Sun

Wang

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…The field of urology encompasses disorders of the urinary tract and the genital system, both benign and malignant. 1 Most men and women with urological disorders hugely suffer from a decreased quality of life (QoL) ultimately leading to economic burden. 2 , 3 Urological disorders include urinary tract infections (UTIs), kidney stones, problems with bladder control and prostate, among others.…”

Section: Introductionmentioning

confidence: 99%

“…The pathologies of each urological disorder are different, and there is still much progress to be made in available therapeutic options in order to minimize adverse events (AEs) and provide effective care. 1 The conservative approach to treatment remains watchful waiting (WW), behavioral and dietary modifications till date. When conservative treatment fails to cure the disease, medical therapy with either α 1 -adrenoceptor antagonists (α 1 -blockers), 5α-reductase inhibitors, muscarinic receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, phytotherapy or β-3 agonist in monotherapy or in combination is preferred.…”

Section: Introductionmentioning

confidence: 99%

“…In an era of an increasing array of treatment options, it has become of utmost clinical importance to refine therapeutic strategies in order to optimize efficacy while limiting systemic toxicity. 1 Urological treatment often carries a high rate of undesirable AEs leading to greater rates of patient noncompliance. 1 …”

Section: Introductionmentioning

confidence: 99%

“… 1 Urological treatment often carries a high rate of undesirable AEs leading to greater rates of patient noncompliance. 1 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review

Jin-dan¹,

Wang²,

Xie³

2022

DDDT

View full text Add to dashboard Cite

Use of α-androgenic receptor blockers remains a mainstay therapeutic approach for the treatment of urological diseases. Silodosin is recommended over other α-blockers for the treatment of lower urinary tract symptoms (LUTS) and benign prostate hyperplasia (BPH), due to its high α 1A uroselectivity. Current research data suggest that silodosin is efficacious in the management of various urological diseases. Thus, we herein review the current evidence of silodosin related to its efficacy and tolerability and appraise the available literature that might ultimately aid in management of various urological conditions at routine clinical practice. Literature reveals that silodosin is beneficial in improving nocturia events related to LUTS/BPH. Silodosin exerts effect on relaxing muscles involved in detrusor obstruction, therefore prolonging the need for patients undergoing invasive surgery. Silodosin treatment, either as a monotherapy or combination, significantly improves International Prostate Symptom Score (IPSS) including both storage and voiding symptoms in patients with BPH/LUTS. Patients on other treatment therapies such as phosphodiesterase 5 inhibitors or other α-blockers are well managed with this drug. Steadily, silodosin has proved beneficial in the treatment of other urological disorders such as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), overactive bladder/acute urinary retention (AUR), premature ejaculation (PE), and prostate cancer post brachytherapy-induced progression. In patients with distal ureteral stones, silodosin treatment is beneficial in decreasing stone expulsion time without affecting stone expulsion rate or analgesic need. Moreover, there were significant improvements in intravaginal ejaculation latency time, quality of life scores, and decrease in PE profile among patients with PE. Silodosin has also demonstrated promising results in increasing the likelihood of successful trial without catheter in patients with AUR and those taking antihypertensive drugs. Reports from Phase II studies have shown promising role of silodosin in the treatment of CP/CPPS as well as facilitating ureteral stone passage. From the robust data in this review, further silodosin treatment strategies in the management of different urological conditions need to be focused on.

show abstract

Preparation and properties of chitosan/dialdehyde sodium alginate/dopamine magnetic drug-delivery hydrogels

Chen,

Deng,

Tian

et al. 2024

Colloids and Surfaces A: Physicochemical and Engineering Aspect

View full text Add to dashboard Cite

Current Therapeutic Strategies in Clinical Urology

Cited by 6 publications

References 98 publications

Injectable, Adhesive, and Self-Healing Composite Hydrogels Loaded With Oxybutynin Hydrochloride for the Treatment of Overactive Bladder in Rats

Injectable, Adhesive, and Self-Healing Composite Hydrogels Loaded With Oxybutynin Hydrochloride for the Treatment of Overactive Bladder in Rats

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review

Preparation and properties of chitosan/dialdehyde sodium alginate/dopamine magnetic drug-delivery hydrogels

Contact Info

Product

Resources

About